

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No potential equality issues were identified during scoping consultation. It was mentioned at the scoping workshop that expert multi-disciplinary teams are not available in all areas of the UK, requiring travel. The clinical expert present at the scoping workshop meeting noted that tocilizumab did not need to be given in a specialist centre and therefore no equality issues were recorded at the workshop.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised in any of the submission made during the course of the appraisal.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified by the Committee.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable as the preliminary recommendations are 'no' and 'a minded no'.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equality issues were identified by the Committee and this has been stated in the appraisal consultation document.

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 6 October 2011

**Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional equality issues were identified during consultation on the appraisal consultation document.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a

specific group to access the technology compared with other groups?  
If so, what are the barriers to access for the specific group?

No recommendations have been made that make it more difficult for any specific group to access the technology.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equality issues were identified by the Committee and this has been stated in the 'Summary of Appraisal Committee's key conclusions' in the final appraisal document.

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 01/12/2011